IQWiG sees benefits for Triumeq and Eperzan

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has announced its latest findings regarding added benefit of Triumeq (dolutegravir/abacavir/lamivudine), a treatment for HIV from ViiV Healthcare, a joint venture of which UK pharma major GlaxoSmithKline (LSE: GSK) is the majority shareholder, and GSK’s diabetes drug Eperzan (albiglutide), coming to mostly favorable conclusions.

The IQWiG, which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

According to the findings, there is an indication that adults who have not been treated for their HIV infection have considerable added benefit from treatment with the new fixed-dose combination. However, an added benefit versus the appropriate comparator therapy is not proven for adults with antiretroviral pre-treatment and for adolescents with and without pre-treatment, because suitable study data are lacking.